



## DAFTAR PUSTAKA

- Afaq, A., Shahid, E., and Hasan, K.S. (2013). Effectiveness of Intravitreal Bevacizumab in Various Ocular Disease. *Pak J Ophthalmol* 2013, vol. 29 No 2: 73-79.
- Deng ,Y., Qiao, L., Du M., Qu C., Wan L, Li J, *et al.* (2021). Age-related macular degeneration: Epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy. *Genes & Diseases*. Available from: <https://doi.org/10.1016/j.gendis.2021.02.0092352-3042>.
- Deana, G.K., Secord, A.A. (2011). Antiangiogenic therapies in epithelial ovarian cancer. *Cancer Control*;18(1):31-43.
- Falavarjani, K.G. and Nguyen, Q.D. (2013). Adverse Events and Complication Associated with Intravitreal Injection of Anti-VEGF Agents: a Review of Literature. *Eye* (2013) 27: 787-794.
- Fleckenstein, M. *et al.* (2021) “Age-related macular degeneration,” *Nature Reviews Disease Primers*. Nature Research. Available at: <https://doi.org/10.1038/s41572-021-00265-2>.
- Hadziahmetovic, M. and Malek, G. (2021) “Age-Related Macular Degeneration Revisited: From Pathology and Cellular Stress to Potential Therapies,” *Frontiers in Cell and Developmental Biology*. Frontiers Media S.A. Available at: <https://doi.org/10.3389/fcell.2020.612812>.
- Haritoglou, C. (2007). Intravitreal Bevacizumab in Diabetic Macular Edema Improved Visual Acuity, Retinal Thickness. *Retina today*, Januari/Februari 2007: 24-25.
- Harrison Daiber, A.F., and Gnugnoli Affiliations, D.M. (2021). *Visual Acuity Continuing Education Activity*. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK563298/?report=printable>.
- Heir, J.S., Brown, D.M., Chong, V., Korobelnik, J.F., Kaiser, P.K., Nguyen, Q.D., Kirchhof , B., Ho A, Ogura, Y., Yancopoulos, G.D., Dkk. (2012). Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. *Ophthalmology*. 119:2537– 2548.
- Holekamp, N.M. (2019). Review of neovascular age- related macular degeneration treatment options. *Am. J. Manag. Care*.
- Kanduri, S. (2020). “03; 02,” *International Journal of Retina (IJRETINA)* 2020, 03, p. 2.
- Kazazi-Hyseni, F., Beijnen, J.H. and Schellens, J.H.M. (2010). Bevacizumab, *The Oncologist*, 15(8), pp. 819–825. Available from: <https://doi.org/10.1634/theoncologist.2009-0317>.



- Kementerian Kesehatan Republik Indonesia. (2018). Infodatin: Pusat Data dan Informasi Kementerian Kesehatan RI Situasi Gangguan Penglihatan. Jakarta: Kementerian Kesehatan Republik Indonesia.
- Kimoto, K. and Kubota, T. (2012). Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability. *Journal of Ophthalmology* vol 2012: 1-11.
- Klein R, Klein BE, Marino EK, Kuller LH, Furberg C, Burke GL, et al. Early age-related maculopathy in the cardiovascular health study. *Ophthalmology*. 2003;110(1):25-33.
- Kumaran, G.C., Jayson, G.C., Clamp, A.R. (2009) Antiangiogenic drug in ovarian cancer. *BJ Cancer*;100:1-7.
- Makita, L.S. *et al.* (2021) "Interleukin-1 $\beta$ -31 (rs1143627) genetic variant and the risk of age-related macular degeneration in the Brazilian population," *Ophthalmic Genetics*, 42(5), pp. 533–538. Available at: <https://doi.org/10.1080/13816810.2021.1929337>.
- Marchiori LLM, Doi MY, Marchiori GM, de Souza GV, Poli-Frederico RC, Ciquinato DSA. Interleukin-1 alpha gene polymorphism (IL-1 $\alpha$ ) and susceptibility to tinnitus in the elderly. *Noise Health*. 2019 Mar-Apr;21(99):77-82. doi: 10.4103/nah.NAH\_67\_18. PMID: 32174642; PMCID: PMC7158897.
- Rosenfeld, P.J., Maguire, M.G., Fine, S.L. (2006). Ranibizumab and Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration: two year results. *N Eng J Med* 2006; 355: 1419-1431.
- Shima, C., Sakaguchi, H., Gomi, F., Kamei, M., Ikuno, Y., Oshima, Y., *et al.* (2008). Complications in Patients after Intravitreal Injections of Bevacizumab. *Acta Ophthalmol* 2008; 86: 372-376.
- Stahl, A. (2020) "Diagnostik und Therapie der altersabhängigen Makuladegeneration," *Deutsches Arzteblatt International*, 117(29–30), pp. 513–520. Available at: <https://doi.org/10.3238/arztebl.2020.0513>.
- Surabhi Ruia, A. and Kaufman Affiliations, E.J. (2021) *Macular Degeneration Continuing Education Activity*. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK560778/?report=printable>.
- Varma, P. and Walia, S. (2013). Bevacizumab (Avastin) for Ocular Disorders. *IPJR Vol 3, Issue 4*: 59-68.
- World Health Organization. (2022). Blindness and vision impairment. Tersedia dari: <https://www.who.int/news-room/fact-sheets/detail/blindness-and-visual-impairment>.



- Wong, L.W., Su, X., Li X., Cheung, C.M., Klein, R., Cheng, C.Y., dan Wong, T.Y. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. *The Lancet – Global Health*. 2014; 2(2): e106-e116.
- Yang, S., Zhao, J. and Sun, X. (2016) “Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: A comprehensive review,” *Drug Design, Development and Therapy*. Dove Medical Press Ltd., pp. 1857–1867. Available at: <https://doi.org/10.2147/DDDT.S97653>.